ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.

Article Details

Citation

Copy to clipboard

Triola G, Wetzel S, Ellinger B, Koch MA, Hubel K, Rauh D, Waldmann H

ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.

Bioorg Med Chem. 2009 Feb 1;17(3):1079-87. doi: 10.1016/j.bmc.2008.02.046. Epub 2008 Feb 16.

PubMed ID

18321716 [ View in PubMed

]

Abstract

D-Alanine-D-alanine ligase (DDl) is an essential enzyme in bacterial cell wall biosynthesis and an important target for developing new antibiotics. Here, we describe a new approach to identify new inhibitor scaffolds for DDl based on similarity in the ATP binding region of different kinases and DDl. After an initial screening of several protein kinase inhibitors, we found that the Brutons's tyrosine kinase inhibitor LFM-A13, an analog of the Leflunomide metabolite A771726, inhibits DDl with a K(i) of 185 microM. A series of malononitrilamide and salicylamide derivatives of LFM-A13 has been synthesized to confirm the validity of this scaffold as an inhibitor of DDl.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Olomoucine	Cyclin-dependent kinase 2	IC 50 (nM)	7000	N/A	N/A	Details